Biological
20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_4
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Other(3)
Detailed Status
unknown3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
unknown3100%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_4
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
NCT03962881
unknownphase_4
Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
NCT03962816
unknownphase_4
Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients
NCT03962803
Clinical Trials (3)
Showing 3 of 3 trials
NCT03962881Phase 4
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
NCT03962816Phase 4
Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
NCT03962803Phase 4
Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3